Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 103.13 +0.50 (0.49%)
price chart
Johnson & Johnson to Begin Testing Ebola Vaccine in January
Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
Johnson & Johnson plans Ebola vaccine testing  KSN-TV
Testing for Ebola Vaccines to Start Soon, WHO Says  New York Times
Related articles »  
Johnson & Johnson's DePuy wins first trial over Pinnacle hips
NEW YORK/DALLAS (Reuters) - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.
Johnson & Johnson (JNJ) Stock Rises Today Following Texas Lawsuit Dismissal
Johnson & Johnson Wins First Pinnacle Hip Implant Trial  Businessweek
Related articles »  
Johnson & Johnson Recalls Contaminated Xarelto
Microbial contamination in samples of the blockbuster blood thinner Xarelto - used to prevent blood clots and strokes - caused Johnson & Johnson's Janssen unit to recall 13,500 bottles of the drug this week. The recall comes shortly after several new ...
Related articles »  
UPDATE 2-Johnson & Johnson's DePuy wins first trial over Pinnacle hips
(Rewrites throughout, adds trial background and plaintiffs' lawyer quote, adds Dallas dateline). By Jessica Dye and Lisa Maria Garza.
Johnson & Johnson to Buy Biotech Company Alios BioPharma
The deal has been approved by the boards of both companies, and is the first acquisition in some time for Johnson & Johnson, which has been more focused on selling assets than buying them this year. In March, Johnson & Johnson sold its K-Y brand of ...
Johnson & Johnson to buy private drug developer for $1.75 billion  Reuters
What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences  Barron's (blog)
Related articles »  
5 Things Johnson & Johnson's Management Wants You to Know
In spite of divesting some of its noncore businesses and experiencing negative currency translation headwinds, Johnson & Johnson managed to grow its revenue by better than 5%, while its EPS improved by 10%. On the surface it looked like a great report.
Johnson & Johnson Share price: Healthcare Aristocrat Leads Recovery on ...  iNVEZZ
Related articles »  
Ebola: Johnson & Johnson to start vaccine trials in January
Johnson & Johnson is to start testing its Ebola vaccine candidate in January after the World Health Organisation (WHO) and world leaders asked it and other companies to accelerate their research programmes.
Related articles »  
Is Johnson & Johnson's Worst Nightmare Becoming Reality?
Johnson & Johnson (NYSE: JNJ ) has been one of the few top healthcare companies to post strong growth within its pharmaceutical segment this year.
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Higher Today
NEW YORK (TheStreet) -- Shares of Johnson & Johnson (JNJ) are up 1.61% to $101.98 in pre-market trade after it was reported this morning that the company plans to have 250,000 doses of an experimental Ebola vaccine ready for use in clinical trials in ...
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part IV (JNJ)
For Part III, I provided sensitivity modeling of both investment value growth and dividend growth under a range of share price and dividend growth projections at a constant PE ratio.